described. CSE was prepared by combusting 1 Marlboro cigarette through 25 ml of media. Cell viability was determined after primary nasal epithelial cells (PNECs) were stimulated with 5% CSE for 24 h (caspase 3 levels determined after 4 h), in the presence or absence of 20 mM N-acetylcyesteine (NAC). In separate experiments, cultures were stimulated with *Pseudomonas aeruginosa* lipopolysaccharide (PA LPS) for 24 h (0 - 30 µg/ml), and the effects of pre-incubation with CSE=20 mM NAC for 4 h evaluated in terms of cytokine release. Phospho-NF-κB activity was determined after 1 h PA LPS exposure. Apoptosis was evaluated using annexin-V staining and the terminal transferase-mediated dUTP nick end-labeling (TUNEL) method.

**Results**  5% CSE (4 h) exposure was immunosuppressive in PNEC cultures for both IL-8 and IL-6 release (0.53 fold reduction in IL-8 and 0.49 fold reduction in IL-6 release after stimulation with 30 µg/ml PA LPS for 24 h). 4 h exposure to CSE heightened active caspase 3 levels, and a 24 h exposure induced both early and late apoptosis established by annexin-V staining (Table 1). Apoptosis was confirmed using the TUNEL assay. All of these effects were mitigated with the addition of 20 mM NAC to the CSE (0.65 fold reduction in IL-8 and 0.75 fold reduction in IL-6 release after stimulation with 30µg/ml PA LPS for 24 h).

**Conclusions**  A 4 h CSE exposure was immunosuppressive in PNEC cultures and induced apoptosis. Reactive oxidative species are at least partially responsible for these observations.

Research funded by NI RDO.

---

**Abstract P251 Table 1** Annexin-V analysis of 5% CSE=20 mM NAC treatment in PNEC Cultures.

<table>
<thead>
<tr>
<th></th>
<th>Viable</th>
<th>Early Apoptotic</th>
<th>Late Apoptotic</th>
<th>Necrotic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control 24 h</td>
<td>99.4%</td>
<td>0.4%</td>
<td>0.1%</td>
<td>0.1%</td>
</tr>
<tr>
<td>5% CSE 24 h</td>
<td>29.1%</td>
<td>47.7%</td>
<td>21.2%</td>
<td>2.0%</td>
</tr>
<tr>
<td>NAC 6 5% CSE 24 h</td>
<td>74.0%</td>
<td>18.3%</td>
<td>4.8%</td>
<td>2.9%</td>
</tr>
</tbody>
</table>

---

**P252**  **PD-1 EXPRESSION ON HUMAN LUNG T CELLS IN HEALTH AND COPD**  
doi:10.1136/thoraxjnl-2012-202678.344

RT McKendry, CM Spalluto, KJ Staples, TMA Wilkinson. The University of Southampton, Southampton, United Kingdom

**Introduction and Objectives**  Patient s with chronic obstructive pulmonary disease (COPD) are susceptible to the effects of recurrent respiratory infections despite increased numbers of CD8+ T cells in the lungs. We hypothesised that the inability of CD8+ T cells to successfully combat respiratory pathogens in COPD may be due to T cell “exhaustion” - a phenomenon described in chronic infections. Exhausted CD8+ T cells have significantly reduced cytotoxicity and inflammatory cytokine release. Exhaustion is thought to be initiated by the binding of PD-1 on T cells to its ligand (PD-L1) which is expressed on epithelial cells and macrophages. PD-1 expression is upregulated in murine models of acute and chronic viral infection, but this has yet to be elucidated in human cells.

We aimed to identify and quantify PD-1+ CD4+ and CD8+ T cells and cells expressing PD-L1 in the lungs of COPD patients and non-COPD controls.

**Methods**  Lung tissue from patients undergoing surgery was digested using collagenase to form single-cell suspensions. Lung T cells were identified as populations of CD45+CD3+ cells which were either CD4+CD8- or CD4-CD8+. T cells expressing PD-1 were quantified by multi-colour flow cytometry. Patients with a FEV1/FVC ratio <70% were defined as having COPD.

**Results**  The proportion of CD8+ T cells in the COPD lung (mean expression=40.87%, SD=14.67) was significantly higher (p=0.013, students t-test) than in non-COPD (mean expression=26.74%, SD=11.12), reflecting previous findings. PD-1 expression in CD4+ T cells appeared to be lower in COPD (mean expression=39.91%, SD=13.02) than non-COPD (mean expression=50.53%, sd=13.05) but this was not significant. PD-1 expressing CD4+ cells (mean expression=2.17%, SD=1.4) and CD8+ cells (mean expression=6.02%, sd=5.73) were detected in tissue, but not in the blood of the same patients. PD-L1 was undetectable on lung epithelial cells but was expressed on macrophages (mean expression = 2.85%, SD=1.91).

**Conclusion**  Elements of the exhaustion pathway are expressed in the human lung in stable COPD. Further work is needed to clarify if there is an upregulation of this pathway in COPD that may explain the susceptibility of these patients to viral exacerbation. Exhaustion of cells recognising respiratory pathogens may have a significant role in COPD outcomes and requires further elucidation.

---

**P253**  **ASSOCIATION OF DEFECTIVE MONOCYTE-DERIVED MACROPHAGE PHAGOCYTOSIS WITH clinicaL PHENOTYPES IN STABLE COPD**  
doi:10.1136/thoraxjnl-2012-202678.345

1R Singh, *XX Chana, 1L Wright, 1DS Garcha, 1BS Kowlessar, 1ARC Patel, 1AJ Mackay, 2PS Fenwick, 1GC Donaldson, 1PJ Barnes, 1JA Wiedzica, 1LE Donnelly. 1Centre for Respiratory Medicine, UCL, London, UK, 2Airway Disease Section, NHLI, Imperial College London, London, UK. 1Centre for Clinical Microbiology, UCL, London, UK

**Introduction**  Macrophages play an important role in clearing inhaled particles and bacteria from the lung, thus maintaining its sterility. Defective phagocytosis of bacteria has been demonstrated in both alveolar and monocyte-derived macrophages (MDMs) from COPD patients and may play a role in the aetiology of the frequent exacerbator phenotype. We hypothesised that defective phagocytosis may also be associated with lower airway bacterial colonisation (LAB) and other clinical parameters in stable COPD.

**Methods**  Whole blood and sputa were collected from stable patients in the London COPD cohort. Stable COPD was defined as no symptom-defined exacerbations recorded on prospectively completed diary cards in the preceding four weeks and subsequent two weeks. Monocyes were isolated from the whole blood and cultured with GM-CSF (2 ng/ml) for 12 days to generate MDMs. MDM phagocytosis of fluorescein-stained polystyrene beads, *Haemophilus influenzae* (HI) and *Streptococcus pneumoniae* (SP) was measured by fluorimetry. LABC was defined as detection of HI, SP or *Moraxella catarrhalis* (MC) in sputum using quantitative PCR.

**Results**  MDMs were cultured from 26 COPD patients. 54% were male, mean age 70.0 years (SD 8.3), FEV, predicted 55.3% (20.3), 13 patients (50%) with LABC did not demonstrate significant associations were demonstrated between exacerbation frequency and phagocytosis of inert beads or SF (p=0.27 and p=0.22 respectively). 15 patients (50%) with LABC did not demonstrate any significant difference in phagocytosis of either beads (p=0.29, HI (p=0.66) or SF (p=0.88) compared with non-colonised patients. There was no significant association between phagocytosis of beads, HI or SF with age, FEV%, predicted, smoking pack year history, ICS dose or BMI (all p>0.05).

**Conclusion**  In stable COPD patients, decreasing phagocytosis of HI was significantly less with increasing exacerbation frequency (p=0.002, r=-0.58, Figure 1), although no significant associations were demonstrated between exacerbation frequency and phagocytosis of inert beads or SF (p=0.27 and p=0.22 respectively). 15 patients (50%) with LABC did not demonstrate any significant difference in phagocytosis of either beads (p=0.29, HI (p=0.66) or SF (p=0.88) compared with non-colonised patients. There was no significant association between phagocytosis of beads, HI or SF with age, FEV%, predicted, smoking pack year history, ICS dose or BMI (all p>0.05).
Background Matrix metalloprotease (MMP)-12 is a key protease in COPD which cleaves pulmonary extracellular matrix and non-matrix substrates. Variation in MMP-12 activity affects severity of COPD which cleaves pulmonary extracellular matrix and non-matrix substrates may lead to the development of drugs for COPD with reduced side effects compared to the broader spectrum MMP inhibitors.

Aims To identify MMP-12 substrates of relevance to COPD and determine how their activity affects disease progression in vivo and in vitro.

Methods In vitro cleavage assays: After literature review the pro-inflammatory mediators osteopontin and tumour necrosis factor (TNF)-α were selected as potential MMP-12 substrates in COPD. Both were incubated with MMP-12 and reaction products analysed by silver stain and western blot. EDTA was used as a metalloprotease inhibitor and thrombin as positive control. COPD cohort: Patients with COPD were recruited during exacerbations at the Nottingham University Hospitals NHS Trust. Sputum, lung function and other in vivo parameters were analysed by western blot for proteins of interest. The study was approved by the local research ethics committee and all patients gave informed consent.

Results MMP-12 cleaved osteopontin and pro-TNF-α in a dose and time-dependent manner when visualised by silver staining. Cleavage was dependent on MMP-12 activity as it was inhibited by EDTA. Western blot analysis was performed on sputum of patients with COPD and demonstrated by western blotting, ELISA and casein zymography. Western blot analysis of sputum with anti-osteopontin antibodies showed a similar band signature to the in vitro cleavage suggesting osteopontin is cleaved in the airways of patients with COPD.

Discussion MMP-12 possesses proteolytic activity against osteopontin and pro-TNF-α in vitro. MMP-12, osteopontin and TNFα are present in COPD sputum and our data suggest that MMP-12 may target osteopontin in COPD. Further work is needed to determine the precise mechanisms of such MMP-12 substrate activity in COPD.